Michelle Levin
Optometrist · Hialeah, FLNPI 1225318975
Payments from drug & device makers
Across 187 payments — averaging $44.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Coopervision Inc.$1K
- Mallinckrodt Hospital Products Inc.$989
- Johnson & Johnson Vision Care, Inc.$479
- Optovue, Inc.$376
- Bausch & Lomb Americas Inc.$372
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$1251%
- Food & beverage$8,21799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $1,644 |
| Coopervision Inc. | 19 | $1,222 |
| Mallinckrodt Hospital Products Inc. | 34 | $989 |
| Johnson & Johnson Vision Care, Inc. | 4 | $479 |
| Optovue, Inc. | 6 | $376 |
| Bausch & Lomb Americas Inc. | 8 | $372 |
| Sight Sciences, Inc. | 3 | $353 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $347 |
| Sun Pharmaceutical Industries Inc. | 7 | $324 |
| Shire North American Group Inc | 6 | $293 |
| Oyster Point Pharma, Inc. | 14 | $285 |
| Biotissue Holdings Inc. | 11 | $256 |
| ANI Pharmaceuticals, Inc. | 8 | $158 |
| Novartis | 3 | $146 |
| Aerie Pharmaceuticals, Inc. | 7 | $136 |
| NEW World Medical,inc. | 1 | $119 |
| Maculogix, Inc. | 1 | $113 |
| Visionix USA, Inc | 1 | $100 |
| Dompe US, Inc. | 4 | $91 |
| LKC Technologies, Inc. | 1 | $90 |
| Topcon Healthcare, Inc. | 1 | $75 |
| Lombart Brothers, Inc. | 1 | $69 |
| Tarsus Pharmaceuticals, Inc. | 3 | $57 |
| Lumibird Medical Inc. | 1 | $54 |
| Alcon | 2 | $47 |
| Amgen(2 entities) | 2 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| Harrow Eye, LLC | 1 | $27 |
| Thea Pharma Inc. | 1 | $26 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$257
- ULTRA$245
- RESTASIS MULTIDOSE$244
- XIIDRA$229
- VUITY$223
- RESTASIS$147
- TearCare$143
- INFUSE$125
- MIEBO$124
- XELPROS$121
- CEQUA$121
- TearCare SmartLid$115
- TEARCARE(TM) (2.2) SYSTEM KIT$115
- AdaptDx$113
- DURYSTA$110
- ALPHAGAN P$107
- OCT$103
How this compares
$8,342 in reported general payments places this provider in the 90th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 106 | $97,129 |
| LumiganBimatoprost | 93 | $35,810 |
| XiidraLifitegrast | 29 | $29,087 |
| CombiganBrimonidine Tartrate/Timolol | 81 | $28,645 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 258 | $25,123 |
| RhopressaNetarsudil Mesylate | 15 | $6,901 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $6,746 |
| Travoprost | 85 | $6,395 |
| Loteprednol Etabonate | 39 | $5,763 |
| Brimonidine Tartrate | 156 | $5,667 |
| Prednisolone Acetate | 225 | $5,612 |
| VyzultaLatanoprostene Bunod | 14 | $5,553 |
| Latanoprost | 982 | $5,297 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,151 |
| Brinzolamide | 47 | $4,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,644 | $164,168291 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $372 | $34,64043 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $136 | $13,64730 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $347 | $5,76339 claims |
| AlconSimbrinza | $47 | $4,15120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Hialeah
- Michael KynnJacksonville$4.5M
- Christine HalodaJacksonville$3.1M
- Bradley GieddWinter Park$2.5M
- Christopher PearsonLongwood$2.5M
- Mark PerryOrlando$1.6M
- Bryan StamJacksonville Beach$1M
- Oksana SovaJacksonville$841K
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$781K
- Jerry RobbenSt Augustine$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.